What is ritlecitinib studying for alopecia areata?

Ritlecitinib is being studied to understand its effectiveness and patient outcomes in treating alopecia areata in real-world clinical practice. This observational study evaluates how patients respond to the drug outside of controlled trials. Participants will be monitored to see how ritlecitinib affects hair loss and quality of life over time.

Who may be eligible for this alopecia areata clinical trial?

Patients aged 12 years and older diagnosed with alopecia areata by a dermatologist may be eligible. Both males and females can participate. Important factors include not having been treated with ritlecitinib or other JAK inhibitors before and being able to attend regular clinic visits. Please review eligibility criteria for more details.

Is there any cost to participate in this alopecia areata clinical trial?

Study-related care, including the study drug or procedure and all trial visits, is provided at no cost. Personal travel and related expenses may vary and are not guaranteed to be covered. Participants should plan accordingly for any additional costs they might incur.

Actively Recruiting

Age: 12Years +

All Genders

ID06531109

PRESTO - Characterization and Clinical Outcomes of Alopecia Areata Patients Treated With Ritlecitinib in a Real-world Cohort A Multinational, Prospective Observational Study

Led by Pfizer · Updated on 2026-06-01

850

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

Alopecia areata AA is a chronic autoimmune condition causing nonscarring hair loss on the scalp and other body areas, affecting people of all ages, genders, and races. The main types include patchy alopecia, alopecia totalis, and alopecia universalis. Researchers aim to study the real-world effectiveness and patient outcomes of ritlecitinib, a drug approved for treating severe AA in patients 12 years and older, building on results from previous clinical trials. Participants in this observational study will receive ritlecitinib as prescribed by their doctors according to the approved label and standard care practices, independent of the study. The study will follow patients over time to observe treatment patterns, disease progression, and responses to ritlecitinib in routine clinical settings. Treatment dosing and schedules will be determined by physicians based on individual patient needs. Throughout the study, participants will attend regular clinic visits to assess disease severity, hair regrowth, and other clinical features using tools like the Severity of Alopecia Tool score. Patient-reported outcomes such as treatment satisfaction and quality of life will also be collected. Researchers will monitor changes over weeks 24, 48, 72, and 96 to evaluate effectiveness and safety. The study aims to capture comprehensive real-world data on ritlecitinib use in AA patients.

CONDITIONS

Brief Title

Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib

Who Can Participate

Age: 12Years +

All Genders

Eligibility Criteria

You may qualify if you...

Male and female patients aged over 12 years at baseline
Diagnosed with alopecia areata confirmed by a certified dermatologist
Prescribed ritlecitinib as per the product label independent of study enrollment
Signed informed consent (and assent for adolescents as required) obtained
Willing and able to comply with regular clinic visits and complete patient questionnaires

You will not qualify if you...

Diagnosed with other types of alopecia or hair loss diseases (e.g., androgenetic alopecia, traction alopecia, scarring alopecia, telogen effluvium)
Diagnosed with scalp diseases or systemic diseases affecting hair loss assessment (e.g., psoriasis, dermatitis, lupus erythematosus, thyroiditis)
Previously treated with ritlecitinib or other JAK inhibitors
Investigator site staff, Pfizer employees involved in the study, or their family members

Research Team

Pfizer CT.gov Call Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here